Compare HTLD & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | DRUG |
|---|---|---|
| Founded | 1978 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.1M | 707.1M |
| IPO Year | 1995 | 2020 |
| Metric | HTLD | DRUG |
|---|---|---|
| Price | $10.88 | $82.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $10.00 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 296.8K | 138.6K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $805,709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $23.18 |
| 52 Week High | $12.13 | $123.75 |
| Indicator | HTLD | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 61.14 |
| Support Level | $10.66 | $69.83 |
| Resistance Level | $11.54 | $84.29 |
| Average True Range (ATR) | 0.30 | 5.07 |
| MACD | 0.12 | 1.79 |
| Stochastic Oscillator | 69.47 | 83.28 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.